Company Encyclopedia
View More
name
Talphera
TLPH.US
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc.
4.362 T
TLPH.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking148/182
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-86.48%E
    • Profit Margin-44242.86%E
    • Gross Margin-180200.00%E
  • Growth ScoreD
    • Revenue YoY-90.04%E
    • Net Profit YoY20.85%B
    • Total Assets YoY46.29%A
    • Net Assets YoY98.91%A
  • Cash ScoreE
    • Cash Flow Margin-0.23%D
    • OCF YoY-90.04%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio37.62%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Maxim Group Remains a Buy on Talphera (TLPH)

    Maxim Group's Naz Rahman reiterated a Buy rating on Talphera with a $3.00 price target. Alliance Global Partners also maintained a Buy rating with a $3.50 target. Rahman, focusing on healthcare stocks, has an average return of -9.3% and a 33.33% success rate. The report highlights investment insights on Talphera.

    Tip Ranks·
    US
    TLPH
    +2.29%
    Tip Ranks·
    US
    TLPH
    +2.29%

    Talphera, Inc. Earnings Call: Balancing Achievements and Challenges

    Talphera, Inc. held its Q3 earnings call, highlighting financial stability, regulatory clarity, and enrollment progress. The company completed a $17 million financing deal, with a strategic investment by CorMedix. Positive enrollment in the Nephro study and a breakthrough FDA designation were noted. However, delays in site activation and enrollment challenges could impact timelines. Cost efficiency measures and a strong cash balance were reported. Forward-looking guidance emphasized confidence in the Nefamostat program despite challenges. Investors are watching closely.

    Tip Ranks·
    US
    TLPH
    +2.29%
    Tip Ranks·
    US
    TLPH
    +2.29%

    Talphera shares are trading lower. The company reported Q3 financial results.

    benzinga_article·
    US
    TLPH
    +2.29%
    benzinga_article·
    US
    TLPH
    +2.29%

    Talphera | 10-Q: FY2025 Q3 Revenue: USD 1 K

    LB filings·
    US
    TLPH
    +2.29%
    LB filings·
    US
    TLPH
    +2.29%

    Talphera | 8-K: FY2025 Q3 Revenue: USD 1 K

    LB filings·
    US
    TLPH
    +2.29%
    LB filings·
    US
    TLPH
    +2.29%